ACN Newswire

2024-07-16 20:00

China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating

SHENZHEN, CHINA, July 16, 2024 - (ACN Newswire) - In July 2024, China Medical System Holdings Limited (“CMS” or the “Group”) has once again been recognized for its outstanding performance and continuous progress in sustainable development. CMS was reincluded in the 2024 Sustainability Yearbook (China Edition) issued by S&P Global, a global-leading corporate sustainability assessment institution, and maintained its "AA" rating in the updated MSCI (Morgan Stanley Capital International) ESG Rating Report.

Re-including in S&P Global's Sustainability Yearbook (China Edition)

The S&P Global's 2024 Sustainability Yearbook (China Edition) has been released. With an CSA score of 51 that surpassing 91% global peers in the industry, CMS stood out among more than 1,700 evaluated Chinese companies to be reincluded in the China Yearbook, becoming one of the five selected companies in the pharmaceutical industry.

Receiving "AA" once again in MSCI ESG Rating

In July, MSCI has released the latest ESG rating report for CMS. The Group has maintained "AA" rating, being positioned at the industry leading level globally.

CMS is committed to its ESG vision of "becoming a world-leading sustainable pharmaceutical enterprise," continuously promoting the deep integration of sustainability concepts with its development strategy. The Group has established an ESG strategy covering various dimensions in operation, along with the Group's mission and vision, and the expectations of stakeholders. Through a robust governance structure, CMS continuously strengthens ESG management and practices to facilitate the achievement of its ESG strategic goals.

Receiving high appraisal from two international authoritative organizations once again signifies the continuous recognition of the value and effectiveness of CMS's sustainable development and relevant practice. In the future, CMS will continue to strengthen ESG governance and overall performance in corporate operations, social contributions, and environmental protection, and work together with all stakeholders to promote sustainable development and contribute to the realization of a green, healthy and prosperous future of human beings.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

CMS Disclaimer and Forward-Looking Statements

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Disclaimer Statement of MSCI

The use by China Medical System Holdings Ltd. of any MSCI ESG Research LLC or its affiliates (“MSCI”) data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of China Medical System Holdings Ltd. by MSCI. MSCI services and data are the property of MSCI or its information providers, and are provided ‘as-is’ and without warranty. MSCI names and logos are trademarks or service marks of MSCI.

Media Contact
China Medical System Holdings Ltd.
CMS Investor Relations
Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.



Copyright 2024 ACN Newswire. All rights reserved. www.acnnewswire.com

人氣文章
最近7天
1
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
2
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
3
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
4
港股 | 蕭猷華:恒指春節前目標21500點
5
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
6
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
7
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
8
新股上市 | 布魯可傳延遲上市,港交所:FINI顯示有誤,續按上市時間表進行
9
賣地計劃 | 政府今季推一幅東涌住宅地涉745伙,全年供應不達標
10
騰訊 | 被美列中國軍事企業名單,騰訊稱非軍工供應商願與美方解決誤會(附名單)
1
高息定存 | 滙豐3個月港元存息高達3.8厘,6個月3.55厘
2
高息定存 | 銀行高息搶存,東亞上調3個月定存息至3.9厘,花旗加至3.7厘
3
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
4
利率波動難測 如何以債券策略爭取「財息兼收」?
5
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
6
專訪|林本利系列專訪一連三個周五登場,樓市篇:中原指數長線重返180,買樓勿買新樓(有片)
7
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
8
特首述職|習近平讚揚李家超務實進取,中央全力支持帶領各界改革
9
滙控 | 擬推改革削減成本,股價再創17年新高,聖誕鐘真係要買滙豐?
10
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
11
高息定存 | 一周高息合集,華僑1個月定存4厘208日3.8厘
12
中經會 | 明年提高財政赤字率,適時降準降息,穩住樓市股市
13
資源有限窒礙中小企轉型? 營商生態圈助你開拓無限商機!
14
高息定存 | 信銀國際上調1個月定存年息至高達3.88厘
15
2025年環球經濟與輪證投資前瞻
16
居屋2024 | 新一期居屋攪珠結果出爐,預計最快明年第二季揀樓
17
回顧展望-共渡時艱 | 表列機構對今明年本港經濟增長預測
18
高息定存 | 聖誕前夕銀行加存息吸資金,大眾3個月加至3.6厘
19
基建債券 | 基建債券認購100手或以下獲全額配發
20
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
21
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
22
【FOCUS】個人養老金制度升級,一石二鳥未改挑戰
23
回顧展望-樓盡六壬 | 甲廈租金明年料跌9%,華潤頻買民生商場
24
【FOCUS】「無厘頭」減息釀驚嚇,長債失控顯聯儲失信譽
25
【FOCUS】「晶片戰」揮新大棒,技術制華恐適得其反
26
中經會 | 中證監:堅決落實「穩住樓市股市」,維護資本市場穩定
27
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
28
今日焦點股 | 據報螞蟻集團重組架構,劉政或出任首席財務官
29
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
30
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet 賞你】賞 MOKO x Cheeky Cheeky「厚」有福氣利是封 及「熊 MEOW 」火柴盒造型年曆卡!

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

回顧24 展望25

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老